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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. This paper summarises the role of chemotherapy in head and neck cancer management,
recent advances and what the future holds for this modality.
Introduction
Chemotherapy alone cannot cure head and neck cancer.
It is used in conjunction with other treatments, surgery
and radiotherapy (RT), to improve outcomes in terms
of local control, organ preservation with continued
organ function and to decrease the incidence of sub-
clinical micro-metastatic spread.
Chemotherapy is not given routinely for early
primary T1/T2 disease without nodal involvement.
Chemotherapy is given for its direct tumouricidal
effect, at both the local primary and distant metastatic
sites. If given with RT it can have a radio sensitising
effect, making cancer cells more susceptible to RT
and increasing the cancer cell kill. It may be used as
induction chemotherapy (ICT), almost always before
RT rather than surgery. If ICT is used, further chemo-
therapy is usually given with subsequent RT, and this
is known as sequential chemotherapy. More common-
ly, chemotherapy is given only concurrently with radio-
therapy (combined chemoradiotherapy) with only a
minority of patients having induction or sequential
regimens. Combined chemoradiotherapy has been
shown to improve local control and increase survival
where primary surgery has been the definitive treat-
ment in selected populations.
Induction (neoadjuvant) chemotherapy
The response to neoadjuvant chemotherapy could give
important prognostic information, as it can act as a sur-
rogate marker for response to later treatment.
This latter advantage was used in one of the earliest
trials of neoadjuvant chemotherapy for organ preserva-
tion, the ‘Veterans’ trial,1 where patients were given
two cycles of cisplatin and 5-fluorouracil (5-FU), and
if there was a response to chemotherapy patients went
on to have chemotherapy and RT, but if there was no
response, the patients went directly to laryngectomy.
Induction chemotherapy is considered beneficial for
several reasons. If ICT could shrink primary tumour
volumes before the principal treatment of RT or che-
moradiotherapy, this might allow better blood flow
into the tumour allowing a greater tumouricidal dose
of drugs into the tumour and decrease the volume of
hypoxic areas which would decrease the radio-resist-
ance that hypoxic cancer cells show. Improved local
control would lead to a greater chance of organ preser-
vation and functionality. Since surgery and RT are both
locoregional treatments, ICT could theoretically treat
distant subclinical metastatic disease. The response to
ICT could give important prognostic information, as
it can act as a surrogate marker for response to later
treatment.
One of the main evidence sources for the use of
chemotherapy in head and neck cancer is the Meta-ana-
lysis of Chemotherapy in Head and Neck Cancer
(MACH-NC) which was originally published in 2000
and updated in 2007 and 2009.2 This overview
reviewed 87 trials containing data on over 16 000
patients, with overall survival as the primary endpoint.
There was no overall survival benefit with the use of
ICT when compared with primary surgery or RT
alone, although cisplatin and 5-FU delivered as com-
bined chemoradiotherapy did show some benefit. It
also suggested that ICT may reduce the incidence of
distant metastases more effectively than combined
chemoradiotherapy.
Debate continues as to whether ICT followed by
combined chemoradiotherapy is more beneficial than
combined chemoradiotherapy alone. Some large
trials, such as the Spanish Head and Cancer Corpora-
tive Group trial have shown no benefit,3 while others,
such as a large Italian trial comparing ICT followed
by combined chemoradiotherapy to combined chemo-
radiotherapy alone showed significantly improved
overall survival for the former arm.4 Interest was
rekindled in ICT when two trials, one European, and
one from North America, TAX 3235 and TAX 3246
showed a benefit by including a taxane, such as
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docetaxel or paclitaxel in the chemotherapy regimen in
addition to cisplatin and 5-FU. The evidence suggested
that adding a taxane, such as docetaxel or paclitaxel to
cisplatin and 5-FU, i.e. docetaxel/cisplatin/5-FU
(TPF) vs cisplatin/5-FU (PF) did improve survival in
the TPF arm, but at a cost of much higher toxicity.
However, these trials have been criticised for not
using optimal concurrent chemotherapy schedules.
Based on further phase 3 studies (DeCIDE,7
PARADIGM trial and8 TREMPLIN study9) the evi-
dence to date does not suggest ICT is in general bene-
ficial in head and neck cancer.
Usually, induction and sequential regimens are
offered to patients with good performance status,
fewer comorbidities and those with bulky nodal
disease, stage N2b and above, and where surgery is
not appropriate.
Concurrent or concomitant chemotherapy
The main advantage of combined chemoradiotherapy,
over sequential chemotherapy, is the reduced chance
of patients having to stop treatment because of toxicity,
and resulting in breaks in RT, which is radiobiologically
suboptimal and can be detrimental to treatment outcome.
In the MACH-NC trial,2 the use of combined che-
moradiotherapy showed that it gave a survival benefit
when added to RT alone, giving a 6.5 per cent decrease
in mortality at five years, in absolute terms. This benefit
was not seen in patients over 70 years of age. The most
commonly used combined chemoradiotherapy regi-
mens are cisplatin 100 mg/m2 on days 1, 22 and 43
of RT, either alone or with 5-FU, 1 g/day on days
1–4, and then repeated 3 weekly with cisplatin. If 5-
FU is added, the cisplatin dose is usually reduced.
Although this regimen is commonly used, there are
few direct comparisons with other combined chemora-
diotherapy within randomised controlled trials.
Increased toxicity produced by adding platinum
chemotherapy to RT can be considerable. A significant
proportion of patients do not receive all three cycles of
chemotherapy because of toxicity, but one study has
shown no survival difference in patients receiving
two cycles of cisplatin rather than three cycles, but
the RT given was not identical within the arms of
this study.10 chemotherapy toxicity can also interfere
detrimentally with RT delivery causing breaks during
treatment which are associated with poorer outcomes.
If cisplatin is contraindicated because of renal func-
tion status, the presence of neuropathy, tinnitus or deaf-
ness, or where there is a danger of fluid overload with
the necessary pre-hydration used in cisplatin adminis-
tration, carboplatin can be considered as it causes less
nephrotoxicity, ototoxicity and peripheral neuropathy
but is more myelosuppressive. It is not thought to be
as tumouricidal as cisplatin and for this reason it has
now been largely overtaken by the epidermal growth
factor receptor inhibitor, cetuximab in clinical practice
when cisplatin is contraindicated.
Concurrent radio-sensitisers
It is known that tumour cell hypoxia induces radioresis-
tance, and there has been renewed interest in giving
hypoxic cell radiosensitising drugs during RT. The
two most common in use are the antihelminthic drug
nimorazol, which is extensively used in some parts of
Europe, and tirapazamine, an anticoagulant which is
activated in hypoxic environments. Although estab-
lished in some parts of the world, trials are ongoing
with these agents to establish efficacy and with nimor-
azol, patient tolerability.
Chemotherapy and human papilloma virus
(HPV)-positive tumours
Human papilloma virus is known to have an aetio-
logical role in inducing some head and neck cancers,
especially in the oropharynx where HPV infection
may be linked to 50–80 per cent of tumours. There is
evidence from several studies that outcomes are better
following treatment in patients with HPV-positive
tumours. There is also growing evidence that continu-
ing to smoke negates the outcome benefit associated
with HPV positivity.
Given the good prognosis, the question arises if
HPV-positive cancers are being overtreated with stand-
ard head and neck chemoradiotherapy regimens and
being given unnecessary morbidity. At present there is
not enough evidence to alter chemotherapy or indeed
RT treatment regimens depending on the patient’s
HPV status, outside of the context of a clinical trial.
Several trials are now investigating these questions,
most using cetuximab comparing with cisplatin (see
below). These include the RTOG 1016 in the USA,
the De-ESCALATE HPV study in the UK and the
Trans-Tasman Radiotherapy Group 12.01 study in
Australia.
Targeted biological agents
Targeted therapy in head and neck cancer developed
with the recognition that epidermal growth factor
receptor (EGFR) is overexpressed in the majority of
head and neck cancers, up to 90 per cent in some
studies, and is associated with a poorer prognosis.
When a growth factor attaches to its receptor on the
cell surface, cells are stimulated to divide and conse-
quently tumours grow. If the receptor is abnormal
because of a mutation the stimulation to divide may
even occur without growth factors interacting with
the receptor. Cetuximab is a mouse–human chimaeric
monoclonal antibody which binds to the extracellular
portion of EGFR and turns this signalling system off.
In the initial innovative cetuximab trial by Bonner
et al.,11 patients with advanced head and neck cancer
were randomised to receive radical RT with or
without cetuximab. At three years, survival (55 vs 45
per cent) and local control (50 vs 41 per cent) was
better in the patient group who had received cetuxi-
mab.12 Although these initial results were encouraging,
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a major drawback to the study was that, since the study
had started, RT alone as used in this study had been
overtaken as a standard of care by combined chemora-
diotherapy. So, comparing radiation alone vs radiation
plus cetuximab was much less relevant in the context
of contemporary standard practice. Also in the initial
trial patients were not stratified by HPV status.
Despite initial hopes that cetuximab would give less
toxicity than the standard chemotherapy, and can there-
fore be given to older patients and those with a poorer
performance status, it has been shown to have a differ-
ent, although not necessarily less toxic, morbidity profile
in the form of grade 3 and 4 radiation dermatitis. Patients
may also develop an acne-like rash predominantly over
the face, neck and trunk with a more eczema-like condi-
tion at the fingertips and elbows. In a minority of
patients this reaction can be so severe that cetuximab
may need to be stopped as these side effects can
usually be managed by increasing the treatment interval
and supportive care with topical medications. There is
some suggestion that patients who develop this rash
may also have a better tumour response with improved
overall survival.
Other targeted EGFR monoclonal antibodies are
under investigation such as panitumamab or zalutumu-
mab, but to date with less encouraging results showing
no improvement in overall survival.
Another potential target further down this biological
pathway, offering a different mechanism of action is
used by erlotinib, a small molecule inhibitor of
EGFR tyrosine kinase. One phase II trial of erlotinib
given alone or combined with cisplatin, unfortunately
did not show any benefit in outcome for the combin-
ation. Despite this other targets in the epidermal
growth factor receptor pathway are being investigated.
Chemotherapy for recurrent or metastatic
head and neck cancer
Chemotherapy or targeted biological agents may be
indicated for patients with recurrent and/or metastatic
disease but prognosis for patients with metastatic
disease has a median survival of approximately 6–12
months in most studies.
Appropriateness of chemotherapy depends on
several factors such as extent and burden of disease;
whether symptoms are present or not; whether failure
of control has taken place at the primary site only;
and whether there is metastatic disease only or both.
The most important factor often is the fitness and per-
formance status of the patient and whether they could
tolerate the proposed chemotherapy, and how much it
would reduce their pre-treatment quality of life, for
whatever limited survival period they have.
Locoregional failure
In this group of patients where salvage surgery or
retreatment with RT or combined chemoradiotherapy
is being considered, it is important to be aware if
distant metastatic disease is also present and also to
establish that the locoregional recurrent disease is not
a second primary head and neck cancer. Discovering
that metastatic disease is also present is not an absolute
contraindication to salvage treatments at the primary
site, as locoregional failure and metastatic disease can
be considered as two separate problems in the patient’s
management plan. If good palliation at the primary site
or locoregionally can be achieved relatively easily, by a
salvage procedure, the presence of metastatic disease,
especially small volume metastatic disease, should
not necessarily stop treatment to the primary or locore-
gional site. The patients who do better with salvage
treatment are those with smaller volumes of recurrence,
a longer disease-free interval and less comorbidity.
Some particular head and neck subsites such as the
larynx, also have better outcomes.13
Distant metastases
Chemotherapy is often indicated here, as part of a best
supportive care package to improve symptoms, but has
not been shown to significantly extend survival. The
therapeutic window for giving chemotherapy in this
situation would be when the patient still has an appro-
priate performance status to receive and benefit from
chemotherapy, with the trade-off being, an improved
symptom state for the inevitable morbidity caused by
the chemotherapy. The choice of regimen depends on
factors such as performance status, comorbidities,
renal function, estimated physiological reserve of the
patient and the interval since last chemotherapy.
If chemotherapy is to be given for distant metastatic
disease then which regimen is most appropriate
depends on several factors including performance
status, comorbidities present, renal function and the
estimated physiological reserve of the patient. Also
which regimens the patients had before and the interval
since last chemotherapy may be important.
The most common regimens used are cisplatin or
carboplatin with 5-FU. These give an expected
response rate of approximately 30 per cent.
Carboplatin is used more in this palliative metastatic
setting than with induction or concurrent regimens,
because although deemed slightly less effective than
cisplatin; its less toxic side-effect profile, can be seen
to be more appropriate in the palliative setting.
Elderly patients do appear to respond to platinum-
based chemotherapy in the metastatic setting,14 in con-
trast to a lack of benefit in the elderly when used in
primary chemoradiotherapy regimens. Other more
toxic chemotherapy regimens have also been investi-
gated using platinum and a taxane (docetaxel or pacli-
taxel), in combination, but no survival benefit has been
demonstrated.
Cetuximab added to cisplatin and 5-FU, can increase
both response rate and improve short-term survival
slightly as shown in the EXTREME trial,15 but five-
year follow-up published recently in abstract form
shows very low survival for patients in both arms of
the study. The EXTREME study did not allow
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crossover between regimens, so similar results might be
achieved by the use of cisplatin and 5-FU followed by
cetuximab used sequentially. In patients who have
become refractive to cisplatin and 5-FU, cetuximab as
a single agent does have a low response rate of approxi-
mately 10–15 per cent.16,17
Key points
• Concurrent chemoradiotherapy is at present the
standard of care for treatment of locally advanced
head and neck cancer with a confirmed survival
benefit of 6.5 per cent at five years
• Single agent cisplatin, which in the past has been
shown to be as effective as multiple drug regimes,
is now being challenged by the introduction of the
use of taxanes
• Targeted biological agents, such as cetuximab,
have a role to play in both advanced head and
neck cancer and recurrent or metastatic disease
but those roles are still being established
• At present human papilloma virus status does not
alter management regimens, although there are
multiple studies underway examining if less
intense treatment, both with radiotherapy and
chemotherapy, could be given to achieve the
same outcome but with less toxicity
• The potential benefit of neoadjuvant or induction
chemotherapy is being re-examined now, but most
recent work has not shown a substantial benefit
• Elderly patients benefit least in terms of survival
advantagewith the use of concurrent chemotherapy.
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